Comparative study of sildenafil and losartan on pulmonary arterial hypertension

Publish Year: 1398
نوع سند: مقاله کنفرانسی
زبان: English
View: 408

نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

AECPMED02_022

تاریخ نمایه سازی: 28 بهمن 1398

Abstract:

Introduction & Objective: Pulmonary blind disease is a cardiopulmonary disease that causes dilatation and hypertrophy of the right ventricle. The most common and main cause of corpulomelia is pulmonary hypertension. Due to the effect of sildenafil and losartan on reducing pulmonary hypertension, we aimed to compare the efficacy of these two drugs in the treatment of pulmonary blindness. Methods: In this clinical trial study, 40 patients with secondary corpulomele were studied. Doppler echocardiography was performed before entering the study and pulmonary artery pressure was measured. The patients were divided into two groups. One group received losartan and the other group received sildenafil. At the end of 6-month hemi-therapy period, pulmonary pressure echocardiography was again measured in both groups and the results were compared and analyzed. Results: In this clinical trial study, a total of 40 patients with secondary corpulomele were studied. In the losartan group, there were 2 males (60) and 5 females (40) and in the sildenafil group 2 males (1) and 2 females (1). There was a significant difference between zinc pressure after treatment in the Losartan and sildenafil groups (p <0.001). Conclusion: Pulmonary arterial blood pressure was significantly decreased in both groups after sildenafil and losartan. This demonstrates the success of both drugs in lowering pulmonary arterial blood pressure. And according to the numbers obtained, the pulmonary arterial blood pressure caused by sildenafil is greater than about losartan (about 5 times)